PORTLAND, Oregon and PUNE, India, November 16, 2016 /PRNewswire/ -- A new report published by Allied Market Research, titled, " Transplant DiagnosticsMarket -Global Opportunity Analysis and Industry Forecast, 2014 -2022", states that the global transplant diagnostics market was $524.7 million in 2015 and is expected to reach $ 1,031 million by 2022, with a CAGR of 10% from 2016 to 2022. The serological assay technology is the most preferred, which accounted for about half of the market share globally, in 2015. The reagents & consumables segment is projected to remain dominant throughout the forecast period. North America held the leading market position in 2015, and is expected to maintain this trend. (Logo: http://photos.prnewswire.com/prnh/20140911/647229 ) Summary of thetransplant diagnostics market report can be accessed on the website athttps://www.alliedmarketresearch.com/transplant-diagnostics-market Increase in incidence of organ failure owing to growing cases of chronic diseases, rise in ageing population, and increase in focus on R&D is expected to propel the growth of the global transplant diagnostics market. Chronic diseases can lead to organ failure in patients, which could be a significant target audience for transplant diagnostics procedures. However, difficulties in human leukocyte antigen (HLA) sequencing and increasing worldwide organ shortage can hamper the market growth. The reagents & consumables segment accounted for the maximum revenue generation in 2015, owing to the increased number of diagnostics procedures pre and post organ transplantation. The instruments & equipment segment is projected to grow at a CAGR of 9.1% and reach $76.3 million by 2022. Both the technologies, namely non molecular assay and molecular assay hold significant position in the global transplant diagnostics market. However, molecular assay technology segment is projected to grow at the highest CAGR of 12.3%, due to highly accurate results provided by the modern molecular assay technology. According to Hemali Narkhede, Manager, Healthcare Research at Allied Market Research, "The non-molecular assay segment is reported to demonstrate a steady growth, due to advent of technological shift in the market. Molecular assays are expected to dominate the technology segment of the transplant diagnostics market, owing to the highly reliable results provided by these assays. Coupled with this, molecular assays used for performing transplant diagnostics procedures are equipped with highly sophisticated technology such as next-generation sequencing, which is current market trend," she further added.